Shivangee Maurya’s Post

Fair #access for all?   Modern medicines have transformed the lives of many patients, but access to those medicines is not remotely equal for all patients around the world. That’s why the #AccesstoMedicineFoundation keeps a close eye on the situation with its bi-annual Access to Medicine Index. The foundation has published the methodology it will use for its 2024 report to assess, measure and rank the efforts being made by 20 of the world’s largest pharma companies to expand access to their medicines in low- and middle-income countries. It will look at 32 indicators and 81 diseases, conditions and pathogens. Data collection is now under way. Importantly, they have put a greater emphasis on ‘patient reach’ – how many patients have actually been able to access a company’s healthcare products. This increased focus on patient reach is just one of the changes being made to the methodology, with the choice of metrics being informed by interviews with more than 100 global health stakeholders. The last Index, published in 2022, (https://lnkd.in/ggfXRvCt) highlighted that while improvements had been made, the impact of progress remains uneven across low- and middle-income countries. Marginalized populations are particularly vulnerable as, unsurprisingly, are patients in the poorest countries. You can now read the full revised methodology (https://lnkd.in/gX6sxtfe.) The 2024 report is set to be published in November, and will give another fascinating insight into where the inequalities lie, and what industry is doing to improve access globally and close the gaps that persist. It’s going to be interesting to see what advances have been made, and how much more needs to be done. Developing new medicines is an expensive business, and there are no easy answers. What do you think companies should be doing to improve access?

The pharmaceutical sector is constantly evolving to meet the ever-changing needs of patients. With advancements in technology and research, new therapies are being developed every day, offering more convenience and effectiveness to patients. One major trend is the shift towards personalized medicine, where treatments are tailored to individual patients based on their genetic makeup, lifestyle, and other factors. This allows for more targeted and effective therapies, reducing side effects and improving outcomes. Another key development is the rise of telemedicine and digital health platforms, which allow patients to consult with healthcare professionals remotely and access their medications and treatments more conveniently. This has become especially important during the COVID-19 pandemic, as it reduces the need for in-person visits and helps maintain continuity of care. Additionally, the pharmaceutical industry is increasingly focusing on preventative care and early intervention, rather than just treating symptoms after they arise. This includes the development of vaccines, screenings, and lifestyle interventions to prevent diseases before they progress. Overall, the pharmaceutical sector is rapidly evolving to meet the needs of patients in a more convenient and effective manner. With continued advancements in technology and research, we can expect to see even more innovative therapies and treatments in the future. #PharmaceuticalInnovation #PersonalizedMedicine #DigitalHealth

IQVIA Institute Report Publication: The Use of Medicines in the U.S. 2024: Usage and Spending Trends and Outlook to 2028 The U.S. emerged from the COVID-19 pandemic in 2023 and healthcare systems adjusted to the longer-term consequences on the utilization of health services, medicine use, and total expenditure on vaccines and therapeutics. As we examine the past year and look to the future, new areas of interest — most notably treatments for obesity and the implementation of the Inflation Reduction Act – have come to the fore and command attention. At the same time, spending trends have demonstrated a resilience to the broader macroeconomic trends and accelerated to levels not seen in nearly a decade, masked by the declining volume and spending on COVID-19 vaccines and therapeutics. This annual trend report is part of a continued effort to advance our collective knowledge by providing evidence-based research, which can help establish a common foundation for discussion and understanding by all stakeholders. It is intended to contribute to the advancement of health in a system that remains highly fragmented and opaque. https://lnkd.in/e_vXsAci

Domuschiev Impact is on a mission to ensure equitable access to affordable medicines. Our latest blog post explores how price fluctuations and market instability are just two challenges creating treatment barriers. However, through targeted investments, we can help drive the transformation urgently needed to address these challenges effectively. #globalhealth

Dive into the future of #healthcare with our #newblog post on the Advanced Drug Delivery Systems Market! 💊 Discover the pivotal #trends and factors driving the evolution of this #market. 🚀 Spend your #weekend with us and stay ahead in the realm of healthcare advancements! Read the blog now! 👇

🔔New publication alert 🔔 Little is known about how long it takes for new medicines to reach countries with different income levels. Olivier Wouters and Jouni Kuha analyzed data, sourced from IQVIA, on the timing of new drug launches in seventy-five low-, middle-, and high-income markets from 1982 to 2024. The sample captured the majority of essential medicines (as designated by the World Health Organization in the twenty-third Model List of Essential Medicines) that first came into medical use anywhere globally from 1982 onward. Kaplan-Meier estimates were used to quantify delays in launches across countries. They found that from the first launch globally, the median time to availability was: 🌍 2.7 years for high-income countries 🌍 4.5 years for upper-middle-income countries 🌍 6.9 years for lower-middle-income countries 🌍 8.0 years for low-income countries. The gap between richer (high- and upper-middle-income) and poorer (lower-middle- and low-income) countries remained largely unchanged over time. Strategies to address the disparities highlighted by this analysis are urgently needed. https://lnkd.in/ewHtMVZG

PurpleLab presents a study using real-world data to better understand biosimilar adoption variation across healthcare provider specialties. The research evaluates if provider specialty drives biosimilar adoption, explicitly looking at adoption probability difference (APD). Learn more about the study here: https://lnkd.in/etizrxUz #Biosimilars #HealthcareInnovation #PharmaTrends #HealthcareData #RealWorldEvidence #PatientOutcomes

💡Free Virtual Event 👉🏼 Futureproofing Biosimilars and Expanding Patient Access: Discuss the U.S. biosimilars market, the value biosimilars provide to patients, how these medicines fit into the health care system — and what needs to be done to advance adoption. #PatientAccess #Healthcare #Biosimiliars #HealthData #HealthcareSystem

I highly recommend reading this excellent opinion piece by Tim Bierley, a campaigner for Global Justice Now, published on Al Jazeera English. Bierley compellingly argues that while we can't overhaul the existing medicine production model overnight, we must acknowledge that the Big Pharma approach is failing and jeopardizing global health. With drug shortages and the threat of superbugs looming, it's crucial to start thinking boldly and invest in alternatives. #publicpharmaeurope #publicpharma #A2M #health

How do you improve health equity and diversity in pharmaceutical research?